AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-10

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Predicting Gastric Cancer Response to Chemo With Multimodal AI Model

NCT06451393

Gastric Cancer Chemotherapy Effect

RECRUITING

Multi-center and Multi-modal Deep Learning Study of Gastric Cancer

NCT05001321

Stomach Neoplasms

UNKNOWN

Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration

NCT06396143

Locally Advanced Gastric Carcinoma

RECRUITING

Multimodal Model Predicts Recurrence

NCT06690268

Gastric Adenocarcinoma

COMPLETED

Using Radiomics to Predict Neoadjuvant Chemotherapy Efficacy

NCT05465512

Gastric Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study seeks to develop a deep learning model to predict the outcomes of neoadjuvant chemotherapy in patients with gastric cancer. Leveraging participants' CT scans, biopsy pathology images, and clinical profiles, this model aims to forecast the effectiveness of post-neoadjuvant chemotherapy and the subsequent prognosis, thereby aiding in individualized treatment choices for these participants.

Data Collection: The investigators will gather data from 1,800 retrospective cases and 200 prospective cases from multiple hospitals. The retrospective data will be divided into training and testing sets to train and validate the model, respectively. The model's performance will subsequently be evaluated using the prospective dataset.

Clinical Information: This encompasses the participant's gender, age, tumor markers, staging, type, specific treatment plans, pre and post-treatment lab results, etc.

Imaging Data: CT imaging data taken within one month prior to the neoadjuvant chemotherapy, with at least the venous phase CT imaging included.

Pathology Data: Pathology images from a gastric tumor biopsy stained with Hematoxylin and Eosin (HE) taken within one month prior to treatment.

TRG Grading: Based on the pathology report of the surgical samples using the Ryan TRG grading system.

Prognostic Endpoints: The recorded endpoints are a 3-year progression-free survival (PFS) and a 5-year overall survival (OS). All deaths due to non-disease factors are excluded from the prognosis analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Image Pathology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy

This group comprises participants diagnosed with advanced gastric cancer. The participants will be treated with standard neoadjuvant chemotherapy regimens recommended by clinical guidelines. Treatment details, including the generic name of the drugs, dosage form, dosage, frequency, and duration, will be recorded according to the specific regimen.

Neoadjuvant Chemotherapy

Intervention Type DRUG

Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neoadjuvant Chemotherapy

Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older;
* Pathologically diagnosed with advanced gastric cancer in accordance with the American AJCC's TNM staging standards;
* Have not undergone any systematic anti-cancer treatments before neoadjuvant chemotherapy and have not had surgery for local progression or distant metastasis;
* Received standard neoadjuvant chemotherapy as recommended by the clinical guidelines, and have documented treatment details;
* CT imaging and biopsy pathology images strictly taken within one month prior to starting neoadjuvant treatment;
* Patients possess comprehensive preoperative clinical information and post-operative TRG grading.